#Hangzhou #financial results #medical technology #Zylox-Tonbridge

Zylox-Tonbridge Delivers Strong Half-Year Results

Zylox-Tonbridge Medical Technology Co., Ltd., a prominent player in the medical technology sector, has recently disclosed its interim results for the first half of 2025, showcasing remarkable financial growth. The company reported a 31.7% increase in revenue, totaling RMB 482 million compared to the previous year, while net profits skyrocketed by 76%, surpassing RMB 121 million. This impressive performance translates to a net profit margin of 25.1%.

Key Factors Driving Growth

In the half-year ending June 30, 2025, Zylox-Tonbridge's core businesses, specifically within the neurovascular and peripheral vascular intervention sectors, displayed robust performance. Revenue from neurovascular products reached RMB 304 million, marking a 25% year-over-year growth, while revenue from peripheral vascular products surged to RMB 176 million, witnessing an impressive 46.2% increase.

Moreover, the company’s focus on lean operational strategies has paid off, with combined research and development (R&D), sales, and administrative expenses as a percentage of revenue decreasing by 7 percentage points compared to the same period last year, significantly bolstering their profitability.

The international segment also demonstrated strong momentum in H1 2025, reporting RMB 15.72 million in revenue. As of June 30, the company has successfully commercialized 22 products across 27 regions, with over 31 products currently in registration across 23 markets. This expansion highlights a growing global network that encompasses 52 countries, supported by partnerships with more than 60 local distributors. The rapid growth and increasing revenue contributions from international markets signal a new era for Zylox-Tonbridge.

Solid Product Portfolio

Zylox-Tonbridge's success can also be attributed to its well-established, innovative product portfolio. Flagship items including the SilverSnake® Intermediate Catheter Series, neurovascular guidewires, Kylin™ Flow Diverter, and UltraFree® Drug-Coated PTA Balloon Catheter achieved substantial sales growth, reflecting heightened market penetration. Additionally, the Phoenix™ Coil System saw renewal in the Jiangsu provincial procurement program, further optimizing its market position.

As of the reporting period, Zylox-Tonbridge had expanded its product network to encompass over 3,000 hospitals, impacting more than a million medical procedures and providing accessible, high-quality treatment options for patients worldwide.

The company is also committed to addressing unmet clinical needs, continuing to innovate its product line. Noteworthy advancements include the ZYLOX Eagle® Aspiration System and the TONBRIDGE Shunfeng™ Balloon Vascular Closure Device, which recently received regulatory approval, strengthening their already diverse portfolio. In the latter half of 2025, additional product approvals are anticipated for groundbreaking devices like a large-lumen thrombus aspiration catheter and a self-expandable intracranial stent.

Global Expansion Strategy

In a bid to enhance its global reach, Zylox-Tonbridge has significantly increased investments in international R&D, regulatory registrations, and commercialization efforts, marking rapid global growth. Its presence is now established in seven out of the world’s top 10 medical device markets, including France, Germany, and Italy, while also making inroads in emerging markets such as Brazil, India, and South Africa.

Recent regulatory approvals for products like the ZYLOX Unicorn™ Vascular Closure System in Indonesia, marking the company’s first venture into the Southeast Asian market, and the ZYLOX Phoenix™ Peripheral Fibered Detachable Coil Occlusion System in Ecuador, signify its strategic expansion into diverse markets.

As Zylox-Tonbridge continues to promote its mission of